566920-89-6

Upstream product

• 71313-97-8 2-(5-fluoro-2-methoxyphenyl)propan-2-ol 
• 217196-31-1 4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-oxopentanoic acid 
• 452-08-4 2-bromo-4-fluoro-1-methoxybenzene 
• 566920-34-1 4-(5-fluoro-2-methoxyphenyl)-4-methyl-2-oxopentanoic acid ethyl ester 
• 934391-82-9 4-(5-fluoro-2-methoxy-phenyl)-4-methyl-2-oxo-pentanoic acid (1-oxo-1,3-dihydro-isobenzofuran-5-yl)-amide 
• 111823-36-0 [(3,5-dimethylphenyl)methyl]magnesium bromide 

Relevant academic research and scientific papers

COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN

A composition for treating, controlling, reducing, or ameliorating inflammatory pain comprises a dissociated glucocorticoid receptor agonist (“DIGRA”), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof. The composition can comprise an additional anti-inflammatory agent and can be formulated for topical application, injection, or implantation. It may be used in a method of managing post-surgical ocular pain such that it has lower risk of eliciting adverse side effects seen with other therapeutic agents.

Trifluoromethyl group as a pharmacophore: Effect of replacing a CF 3 group on binding and agonist activity of a glucocorticoid receptor ligand

Compound 1, a potent glucocorticoid receptor ligand, contains a quaternary carbon bearing trifluoromethyl and hydroxyl groups. This paper describes the effect of replacing the trifluoromethyl group on binding and agonist activity of the GR ligand 1. The r

Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof

A compound of Formula (I) wherein R1, R2, R3, R4, R5, and R6 are as defined herein, or a tautomer, prodrug, solvate, or salt thereof, pharmaceutical compositions containing such compounds,